US 10,376,569 B2
Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Helen Hoerzer, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); and Harpreet Singh, Muenchen Schwabing (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Dec. 5, 2018, as Appl. No. 16/210,357.
Application 16/210,357 is a continuation of application No. 16/024,164, filed on Jun. 29, 2018, granted, now 10,166,278.
Application 16/024,164 is a continuation of application No. 16/065,681, granted, now 10,213,499, previously published as PCT/EP2016/079059, filed on Nov. 29, 2016.
Claims priority of provisional application 62/270,968, filed on Dec. 22, 2015.
Claims priority of application No. 1522667.3 (GB), filed on Dec. 22, 2015.
Prior Publication US 2019/0091312 A1, Mar. 28, 2019
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 38/17 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C12N 15/115 (2010.01); A61P 35/02 (2006.01); A61K 38/08 (2019.01); C07K 16/28 (2006.01); C07K 16/00 (2006.01); C07K 14/72 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 39/39 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 35/17 (2013.01); A61K 38/08 (2013.01); A61K 38/1709 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 7/06 (2013.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 14/721 (2013.01); C07K 16/00 (2013.01); C07K 16/2833 (2013.01); C12N 15/115 (2013.01); A61K 38/00 (2013.01); A61K 39/39 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/812 (2018.08); C07K 2317/41 (2013.01); C12N 2310/16 (2013.01)] 21 Claims
 
1. A method of treating cancer in a HLA-A*02+ patient having a cancer overexpressing a KDM5B polypeptide comprising the amino acid sequence of SEQ ID NO: 37 and presenting at its surface a peptide consisting of SEQ ID NO: 37 in the context of a complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate the cancer cells,
wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 37 in the context of a complex with an MHC class I molecule in vitro,
wherein the cancer is selected from small cell lung cancer, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), esophageal cancer, urinary bladder cancer, uterine cancer, colon cancer, and head and neck squamous cell carcinoma (HNSCC).